JP2000080047A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2000080047A5 JP2000080047A5 JP1999183299A JP18329999A JP2000080047A5 JP 2000080047 A5 JP2000080047 A5 JP 2000080047A5 JP 1999183299 A JP1999183299 A JP 1999183299A JP 18329999 A JP18329999 A JP 18329999A JP 2000080047 A5 JP2000080047 A5 JP 2000080047A5
- Authority
- JP
- Japan
- Prior art keywords
- medicament according
- appetite suppressant
- insulin sensitizer
- medicament
- salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000003814 drug Substances 0.000 description 16
- 239000002830 appetite depressant Substances 0.000 description 7
- 229940122355 Insulin sensitizer Drugs 0.000 description 5
- GHUUBYQTCDQWRA-UHFFFAOYSA-N Pioglitazone hydrochloride Chemical group Cl.N1=CC(CC)=CC=C1CCOC(C=C1)=CC=C1CC1C(=O)NC(=O)S1 GHUUBYQTCDQWRA-UHFFFAOYSA-N 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229960002827 pioglitazone hydrochloride Drugs 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- ZPXSCAKFGYXMGA-UHFFFAOYSA-N Mazindol Chemical group N12CCN=C2C2=CC=CC=C2C1(O)C1=CC=C(Cl)C=C1 ZPXSCAKFGYXMGA-UHFFFAOYSA-N 0.000 description 2
- YASAKCUCGLMORW-UHFFFAOYSA-N Rosiglitazone Chemical compound C=1C=CC=NC=1N(C)CCOC(C=C1)=CC=C1CC1SC(=O)NC1=O YASAKCUCGLMORW-UHFFFAOYSA-N 0.000 description 2
- 125000000217 alkyl group Chemical group 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 125000004435 hydrogen atom Chemical group [H]* 0.000 description 2
- 229960000299 mazindol Drugs 0.000 description 2
- 125000001424 substituent group Chemical group 0.000 description 2
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- 208000002249 Diabetes Complications Diseases 0.000 description 1
- 206010012655 Diabetic complications Diseases 0.000 description 1
- 208000002705 Glucose Intolerance Diseases 0.000 description 1
- 125000001931 aliphatic group Chemical group 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 125000000623 heterocyclic group Chemical class 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 201000009104 prediabetes syndrome Diseases 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 229960004586 rosiglitazone Drugs 0.000 description 1
- 229960004425 sibutramine Drugs 0.000 description 1
- UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 description 1
- 229910052717 sulfur Chemical group 0.000 description 1
- 125000004434 sulfur atom Chemical group 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP11183299A JP2000080047A (ja) | 1998-06-30 | 1999-06-29 | 医 薬 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP18370098 | 1998-06-30 | ||
| JP10-183700 | 1998-06-30 | ||
| JP11183299A JP2000080047A (ja) | 1998-06-30 | 1999-06-29 | 医 薬 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2000080047A JP2000080047A (ja) | 2000-03-21 |
| JP2000080047A5 true JP2000080047A5 (enExample) | 2006-06-22 |
Family
ID=26501804
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP11183299A Pending JP2000080047A (ja) | 1998-06-30 | 1999-06-29 | 医 薬 |
Country Status (1)
| Country | Link |
|---|---|
| JP (1) | JP2000080047A (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1505974B1 (en) * | 2002-05-17 | 2009-04-22 | Tioga Pharmaceuticals, Inc. | Use of compounds that are effective as selective opiate receptor modulators |
| US7264813B2 (en) | 2003-09-24 | 2007-09-04 | Nikken Sohonsha Corporation | Therapeutic uses of Dunaliella powder |
| CN101801375B (zh) | 2007-01-25 | 2014-01-01 | 韦尔瓦制药有限公司 | 胰岛素增敏剂和治疗方法 |
| PT2136801E (pt) | 2007-03-30 | 2012-12-06 | Tioga Pharmaceuticals Inc | Agonistas kappa-opiáceos para o tratamento do síndrome do intestino irritável com predomínio de diarreia ou alternância |
| SG11201407786XA (en) * | 2012-05-24 | 2015-03-30 | Verva Pharmaceuticals Ltd | A method of weight reduction |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI238064B (en) * | 1995-06-20 | 2005-08-21 | Takeda Chemical Industries Ltd | A pharmaceutical composition for prophylaxis and treatment of diabetes |
| GB9619757D0 (en) * | 1996-09-21 | 1996-11-06 | Knoll Ag | Chemical process |
-
1999
- 1999-06-29 JP JP11183299A patent/JP2000080047A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1236719A4 (en) | NOVEL HETEROCYCLIC COMPOUNDS AND SALTS THEREOF, USE OF THESE COMPOUNDS IN MEDICINE | |
| JP2002543065A5 (enExample) | ||
| CA2514191A1 (en) | Compound inhibiting dipeptidyl peptidase iv | |
| JP2004504388A5 (enExample) | ||
| IN2015DN01132A (enExample) | ||
| RU2002115263A (ru) | 5-членные N-гетероциклические соединения, обладающие гипогликемической и гиполипидемической активностью | |
| JP2003501474A5 (enExample) | ||
| RU2000131183A (ru) | Производные оксииминоалкановой кислоты | |
| MY142551A (en) | Substituted diaryl heterocycles, process for their preparation and their use as medicaments | |
| JP2011527334A5 (enExample) | ||
| JP2005518398A5 (enExample) | ||
| JP2005500312A5 (enExample) | ||
| JP2003335752A5 (enExample) | ||
| JP2009504748A5 (enExample) | ||
| JP2002527474A5 (ja) | 躁病および双極性障害の治療のための医薬 | |
| JP2006507220A5 (enExample) | ||
| JP2005526696A5 (enExample) | ||
| RU2005135441A (ru) | Соединения для лечения метаболических расстройств | |
| NO20070979L (no) | Anvendelse av N-aryldiazaspirasykliske forbindelser i behandling av avhengighet | |
| JP2003534359A5 (enExample) | ||
| JP2002519425A5 (enExample) | ||
| JP2005517677A5 (enExample) | ||
| JP2005529965A5 (enExample) | ||
| CA2522738A1 (en) | Compounds for the treatment of metabolic disorders | |
| JP2005526024A5 (enExample) |